Toronto, Ontario--(Newsfile Corp. - October 23, 2014) - ChroMedX Corp. (CSE:
CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and
point-of-care technologies is pleased to announce that the trademark for the
Company's patented HemoPalm technology has been allowed by the United States
Patent and Trademark Office and will be officially registered when the HemoPalm
is released commercially.
The HemoPalm technology is currently covered by two issued and
one pending patent. The pending patent will be filed internationally in spring
2015, with the intent to extend the patent protection term in the US, and to
seek patent protection at least in Europe and Asia for the extended term.
"ChroMedX continues to build on a strong foundation of
intellectual property detailing the Company's novel in-vitro diagnostic and
point-of-care testing systems. We are pleased to make this announcement and look
forward to the official registration of the HemoPalm trade mark. " said Dr.
Wayne Maddever, P.Eng, President & CEO of ChroMedX Corp.
Furthermore, ChroMedX has recently been assigned U.S. patent
7,807,450 which covers various aspects of the Company's Plasma Extraction
Cartridge, a novel device for the separation of plasma from whole blood at the
point of collection.
The AUF (Automatic Ultra Filtration) patent application was
filed internationally and earlier this year a very favorable written response
was issued by the international searching authority. Last week on behalf of
ChroMedX, the IP law firm Bereskin & Parr filed a demand for
international preliminary examination.
A list of issued and pending patents can be found on the
company's website here: http://www.chromedx.com/intellectual-property/
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the
development of novel medical devices for in vitro diagnostics and point-of-care
testing. The devices are protected by the Company's issued US and pending
international patents, dealing with blood collection, analysis and plasma/serum
processing.
The Company recently announced the engagement of Mr. Marco
Witteveen of the Netherlands as a Business Development Advisor to assist the
Company in the global commercialization of its innovative point of care and in
vitro diagnostics technologies.
Follow ChroMedX Corp.:
Website:
www.chromedx.com
Facebook: facebook.com/chromedxcorp
Twitter: www.twitter.com/Chromedxcorp
Contact
Wayne
Maddever
President, CEO & Director
647-872-9982
W. Clark Kent
Corporate Development
647-519-2646
ckent@chromedx.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS
REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release
contains certain "forward-looking information" within the meaning of applicable
securities law. Forward-looking information is frequently characterized by words
such as "plan", "expect", "project", "intend", "believe", "anticipate",
"estimate" and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements are based on the
opinions and estimates at the date the statements are made, and are subject to a
variety of risks and uncertainties and other factors that could cause actual
events or results to differ materially from those anticipated in the
forward-looking statements including, but not limited to delays or uncertainties
with regulatory approvals, including that of the CSE. There are uncertainties
inherent in forward-looking information, including factors beyond the Company's
control. The Company undertakes no obligation to update forward-looking
information if circumstances or management's estimates or opinions should change
except as required by law. The reader is cautioned not to place undue reliance
on forward-looking statements. Additional information identifying risks and
uncertainties that could affect financial results is contained in the Company's
filings with Canadian securities regulators, which filings are available at
www.sedar.com
© 2024 Canjex Publishing Ltd. All rights reserved.